BioCryst Pharmaceuticals NASDAQ: BCRX expects revenue to land at the upper end of its $625 million to $645 million guidance range this year, CEO Charlie Gayer said at a Jefferies conference, while outlining plans to expand its hereditary angioedema portfolio and add rare-disease assets.








